Ignite Creation Date:
2024-05-06 @ 2:49 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04433988
Status:
WITHDRAWN
Last Update Posted:
2023-01-18
First Post:
2020-06-13
Brief Title:
Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Sponsor:
Sadat City University
Organization:
Sadat City University
Study Overview
Official Title:
Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Status:
WITHDRAWN
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Institutional problems
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
With potential antiviral effects on severe acute respiratory syndrome SARS and as a methyl-xanthine derived inhibitor of phosphodiesterase-4 pentoxifylline basically functions as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects on immune modulation inflammation and oxidative stress As the main regulator of cAMP metabolism posphodiesterase-4 plays a key role in proinflammatory and immune cells Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory cytokines such as TNF-a IL-1 and IL-6 Given its unique impacts on immune modulation homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ failure pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for COVID-19 patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None